A Phase 2 interventional study of NVA237 and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-05-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 46th largest by enrollment, is one of 4 that started in 2007, is one of 19 in phase 2, and was the 2nd registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 82nd largest by enrollment of the 116 interventional ones that give a count, is one of 12 that started in 2007, is one of 21 in phase 2, and was the 9th registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy and safety of glycopyrronium bromide (NVA237) in patients with stable COPD, in comparison to an active comparator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with a history of asthma indicated by (but not limited to):
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
12.5 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
Drug: NVA237
25 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
Drug: NVA237
50 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
Drug: NVA237
100 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
Drug: NVA237
Placebo via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
Drug: Placebo
18 µg od via Handihaler inhaler. Tiotropium was given open-label. At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
Drug: Tiotropium
single-dose dry-powder inhaler (SDDPI)
single-dose dry-powder inhaler (SDDPI)
Handihaler inhaler
Trough Forced Expiratory Volume in 1 Second (FEV1) Following 7 Days of Treatment
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough in FEV1 was defined as the mean of two measurements at 23h 15min and 23h 45min post dosing.
Time frame: Day 7
Least Squares Means of FEV1 (L) at Day 1, by Timepoint
FEV1 was measured at 5, 15, 30 minutes, 1, 2, 3, 4, 5, 23 hours and 15 minutes, and 23 hours and 45 minutes post dose.
Time frame: Day 1
| Milestone | Overall Study |
|---|---|
| Started | 83 |
| Nva237 12.5µg | 55 |
| Nva237 25µg | 51 |
| Nva237 50µg | 53 |
| Nva237 100µg | 54 |
| Placebo | 55 |
| Tiotropium | 55 |
| Completed | 78 |
| Not completed | 5 |
| Withdrew: Adverse event | 3 |
| Withdrew: Withdrawal by subject | 2 |
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough in FEV1 was defined as the mean of two measurements at 23h 15min and 23h 45min post dosing.
| Liters | NVA237 12.5 ug | NVA237 25 ug | NVA237 50 ug | NVA237 100 ug | Placebo | Tiotropium Bromide |
|---|---|---|---|---|---|---|
| Trough Forced Expiratory Volume in 1 Second (FEV1) Following 7 Days of Treatment | 1.317 ± 0.0145 | 1.333 ± 0.0151 | 1.374 ± 0.0148 | 1.385 ± 0.0148 | 1.243 ± 0.0156 | 1.370 ± 0.0145 |
FEV1 was measured at 5, 15, 30 minutes, 1, 2, 3, 4, 5, 23 hours and 15 minutes, and 23 hours and 45 minutes post dose.
| Liters | NVA237 12.5 ug | NVA237 25 ug | NVA237 50 ug | NVA237 100 ug | Placebo | Tiotropium Bromide |
|---|---|---|---|---|---|---|
| Day 1: -45 minutes | 1.25 ± 0.00 | 1.24 ± 0.00 | 1.24 ± 0.00 | 1.24 ± 0.00 | 1.24 ± 0.00 | 1.25 ± 0.00 |
| Day 1: -15 minutes | 1.25 ± 0.00 | 1.26 ± 0.00 | 1.25 ± 0.00 | 1.26 ± 0.00 | 1.26 ± 0.00 | 1.25 ± 0.00 |
| Day 1: 5 minutes | 1.30 ± 0.01 | 1.34 ± 0.01 | 1.34 ± 0.01 | 1.35 ± 0.01 | 1.26 ± 0.01 | 1.31 ± 0.01 |
| Day 1: 15 minutes | 1.36 ± 0.01 | 1.41 ± 0.01 | 1.41 ± 0.01 | 1.41 ± 0.01 | 1.27 ± 0.01 | 1.35 ± 0.01 |
| Day 1: 30 minutes | 1.41 ± 0.01 | 1.44 ± 0.01 | 1.44 ± 0.01 | 1.45 ± 0.01 | 1.28 ± 0.01 | 1.40 ± 0.01 |
| Day 1: 1 hour | 1.42 ± 0.01 | 1.46 ± 0.01 | 1.46 ± 0.01 | 1.48 ± 0.01 | 1.28 ± 0.01 | 1.41 ± 0.01 |
| Day 1: 2 hours | 1.44 ± 0.01 | 1.48 ± 0.01 | 1.50 ± 0.01 | 1.52 ± 0.01 | 1.31 ± 0.01 | 1.45 ± 0.01 |
| Day 1: 3 hours | 1.43 ± 0.01 | 1.48 ± 0.01 | 1.49 ± 0.01 | 1.53 ± 0.01 | 1.30 ± 0.01 | 1.46 ± 0.01 |
| Day 1: 4 hours | 1.41 ± 0.01 | 1.45 ± 0.01 | 1.49 ± 0.01 | 1.52 ± 0.01 | 1.30 ± 0.01 | 1.46 ± 0.01 |
| Day 1: 5 hours | 1.39 ± 0.01 | 1.43 ± 0.01 | 1.44 ± 0.01 | 1.49 ± 0.01 | 1.28 ± 0.01 | 1.45 ± 0.01 |
| Day 1: 23 hours 15 minutes | 1.27 ± 0.01 | 1.29 ± 0.01 | 1.36 ± 0.01 | 1.37 ± 0.01 | 1.24 ± 0.01 | 1.35 ± 0.01 |
| Day 1: 23 hours 45 minutes | 1.29 ± 0.01 | 1.31 ± 0.01 | 1.37 ± 0.01 | 1.39 ± 0.01 | 1.25 ± 0.01 | 1.37 ± 0.01 |
| Trough | 1.28 ± 0.01 | 1.30 ± 0.01 | 1.36 ± 0.01 | 1.38 ± 0.01 | 1.24 ± 0.01 | 1.36 ± 0.01 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NVA237 12.5 ug | — | 0/55 (0%) | 6/55 (10.9%) |
| NVA237 25 ug | — | 0/51 (0%) | 4/51 (7.8%) |
| NVA237 50 ug | — | 1/53 (1.9%) | 1/53 (1.9%) |
| NVA237 100 ug | — | 0/54 (0%) | 2/54 (3.7%) |
| Placebo | — | 0/55 (0%) | 3/55 (5.5%) |
| Tiotropium Bromide | — | 0/54 (0%) | 2/54 (3.7%) |
| Event | NVA237 12.5 ug | NVA237 25 ug | NVA237 50 ug | NVA237 100 ug | Placebo | Tiotropium Bromide |
|---|---|---|---|---|---|---|
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/55 | 0/51 | 1/53 | 0/54 | 0/55 | 0/54 |
| Event | NVA237 12.5 ug | NVA237 25 ug | NVA237 50 ug | NVA237 100 ug | Placebo | Tiotropium Bromide |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 4/55 | 1/51 | 1/53 | 1/54 | 0/55 | 2/54 |
| RhinitisInfections and infestations | 0/55 | 3/51 | 0/53 | 0/54 | 1/55 | 0/54 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/55 | 0/51 | 0/53 | 1/54 | 2/55 | 0/54 |
| Age Continuous(years) | Overall Study |
|---|---|
| Mean | 64.4 ± 9.05 |
| Age, Customized(participants) | Overall Study |
|---|---|
| 40-64 years | 39 |
| >= 65 years | 44 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 14 |
| Male | 69 |
| Race (NIH/OMB)(Participants) | Overall Study |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 25 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 58 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
The record gives a start of Jul 2007 and a primary completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →